Human evidence record · Kisspeptin
Kisspeptin-54 trigger for oocyte maturation in IVF
Kisspeptin induced oocyte maturation across studied doses and pregnancies occurred.
Quick read
Human evidence record
What this study tells us
This is human clinical evidence. Its strength depends on the study design, sample size, comparator, population, duration and the outcome that was actually measured.
Who was studied?
Women undergoing IVF
How many?
n=53
What happened?
Kisspeptin induced oocyte maturation across studied doses and pregnancies occurred.
What stops us overclaiming?
Specialist reproductive setting; cannot be extrapolated to unsupervised fertility or libido use.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Kisspeptin induced oocyte maturation across studied doses and pregnancies occurred.
Study details
Study designDose-ranging clinical study
PopulationWomen undergoing IVF
Sample size53
RouteSubcutaneous
Regimen / exposure1.6, 3.2, 6.4 or 12.8 nmol/kg kisspeptin-54
DurationSingle trigger
ComparatorDose groups
Primary endpoint / questionOocyte maturation
Safety resultStudy context involved specialist fertility monitoring.
Key limitationsSpecialist reproductive setting; cannot be extrapolated to unsupervised fertility or libido use.
Registry / identifierPMID 25036713